Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.50 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8722398 | 0.91 | GRIA1 (0.56) | LNPEPGRIA1ECE1GPR132CMKLR2 | |
| SCHEMBL8722708 | 0.91 | GRIA1 (0.56) | LNPEPGRIA1ECE1GPR132CMKLR2 | |
| SCHEMBL6860349 | 0.90 | ECE1 (0.62) | ECE1GPR132CMKLR2CMKLR1KMT2A | |
| SCHEMBL6860313 | 0.86 | GPR132 (0.61) | GRIA1ECE1GPR132CMKLR2CMKLR1 | |
| SCHEMBL30037402 | 0.86 | GPR132 (0.61) | GRIA1ECE1GPR132CMKLR2CMKLR1 | |
| SCHEMBL1720156 | 0.85 | PPARG (0.62) | LNPEPGRIA1TSHRMDM4MDM2 | |
| SCHEMBL1720157 | 0.85 | PPARG (0.62) | LNPEPGRIA1TSHRMDM4MDM2 | |
| SCHEMBL3928165 | 0.85 | LNPEP (0.67) | LNPEPTSHRMDM4MDM2ERAP2 | |
| SCHEMBL3928164 | 0.85 | LNPEP (0.67) | LNPEPTSHRMDM4MDM2ERAP2 | |
| SCHEMBL7894291 | 0.83 | GPR132 (0.60) | ECE1GPR132CMKLR2CMKLR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| EP-2528898-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | Kareus Therapeutics SA (FR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | LNPEP 893/4885GRIA1 1113/4885TSHR 4654/4885 |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | LNPEP 893/4885GRIA1 1113/4885TSHR 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.